Linshom is the first FDA cleared device capable of practically delivering a predictive respiratory profile to the hospital bedside or patient’s home.
A razor / razor-blade model with 90% gross margins and patents issued worldwide. Validating data from Harvard (BWH) and Cleveland Clinic and SBIR phase 1&2 awards. Addressing a $2B market opportunity in the US where current technology is not transferable to the bedside due to complexity and cost.